November
Medicinal Chemistry
Strategy Meeting East Coast USA 2023
Reinvigorating Productivity in Pharma Biotech Through Advanced Technologies and Innovative Techniques that Interrogate Activity and Mechanisms
Le Meridien Cambridge BostonWhat makes our strategy meetings unique?
Roundtable Discussions
Intimate discussions led by renowned industry experts. Have your voice heard and debate alongside like-minded life science executives.
Unrivalled Networking
With senior delegation from big pharma and innovative biotech from across the East Coast, you can network with peers from different locations, all in one place.
Personalised Agenda
Choose the topics that matter to you. Reserve your place at the roundtable discussions and ensure your whole day delivers the insights you need to hear.
Solutions to your Problems
We’ve partnered with the best solution providers to solve your biggest challenges. Engage in pre-arranged, private meetings to address your specific needs and find a tangible solution.
Industry Researched Topics
We guarantee our agenda is up-to-date and mission critical because its designed by you. We speak to our extended network of senior decision makers to ensure the most important topics are discussed.
Senior Decision Makers
The entire strategy meeting is specifically tailored to the needs and challenges of senior life science professionals. Discover how your peers are dealing with the same challenges as you.
Meet Our 2023 Facilitators
Our panel of facilitators play a key role in shaping the agenda for the day. See who will be bringing their expertise to the table at our Medicinal Chemistry strategy meeting.
Aaron Frank
Director and Head of Computational Chemistry Arrakis Therapeutics
Allen Hopper
VP Drug Discovery Lucy Therapeutics
Andrew L. Roughton, Ph.D
WuXi AppTec Co., Ltd.
Blaise Lippa
Chief Scientific Officer Morphic Therapeutics
Byron DeLaBarre
Chief Technology Officer (CTO) & Head of Platform Pin Therapeutics
Carlos Pedraza
AVP Biology Sai Life Sciences
Ching Kim Tye
mRNA Director, LNP Platform Development Sanofi
Diane Joseph-McCarthy
Executive Director, Bioengineering Technology & Entrepreneurship Center Boston University
Dominic Reynolds
Senior Vice President, Head of Drug Discovery Remix Therapeutics
Dr. Tamsin Mansley
President and Global Head of Application Science Optibrium Inc.
Ed Olhava
Senior Vice President, Preclinical Development IFM Therapeutics
Horst Hemmerle
Chief Scientific Officer Kojin Therapeutics
Ivan Efremov
VP, Head of Medicinal Chemistry Nereid Therapeutics
Jacques Dumas
Chief Scientific Officer Arrakis Therapeutics
Kaicheng Zhu
Head of Operations, Boston Bellen
Kevin Kreutter
Vice President, Drug Discovery Empress Therapeutics
Liang Mao
Senior Director, Head of Developability and Formulation Research WuXi AppTec
Matthew Lucas
VP of Medical Chemistry Third Harmonic Bio
Norman Azoulay
Director – Scientific Products Excelra
Onur Atasoylu
Director, Head of Computational Chemistry Incyte
Rich Heidebrecht
Vice President of Research and Development Glycologix
Robert Goodnow
Head Drug Discovery Sciences Takeda
Sam Baskaran
Director, Medicinal Chemistry WuXi AppTec
Sejal Patel
Vice President Chemistry Scorpion Therapeutics
Shankar Venkatraman
Executive Director, Chemistry IFM Therapeutics
Sonela Cavicke
Vice President of Discovery Business Development Sai Life Sciences Ltd
Xiaoqi (Charles) Chen
VP of Business Development Bellen ChemistryWho Should Attend the Event?
Chief Executive Officers
Executive Vice Presidents
Vice Presidents
Executive Directors
Directors
Global Heads
Responsible For:
Medicinal Chemist
Computational Chemist
Translational
Chemist/Biology
In-Silico/In-vivo/In-vitro Chemist/Biologist
Chemical Biology
Molecular Chemist/Biologist
Hit and Lead Chemist
Small/Large Molecules Chemist
Drug Discovery or Drug Development
See Which Topics Are Discussed at the Strategy Meeting
Roundtable Tracks
1Evaluating the Effectiveness of Computer-Aided Drug Design, Artificial Intelligence and Machine Learning Tools In Fragment-Based Lead Discovery
-Diane Joseph-McCarthy
Executive Director, Bioengineering Technology & Entrepreneurship Center
Boston University
INNOVATIVE AND EMERGING MODALITIES
Building Successful Collaborations in Drug Discovery: Strategies for Effective Partnerships
-Rich Heidebrecht
Vice President of Research and Development
Glycologix
CHEMICAL BIOLOGY, TARGETED PROTEIN DEGRADATION & UNDRUGGABLES
Next-Generation PROTACs: Beyond Traditional Ubiquitin Ligases
-Byron DeLaBarre
Chief Technology Officer (CTO) & Head of Platform
Pin Therapeutics
HIT IDENTIFICATION / LEAD OPTIMIZATION
Leveraging Predictive Model Techniques To Accelerate Hit-To Lead Optimization
-Onur Atasoylu
Director, Head of Computational Chemistry
Incyte
INTEGRATED DRUG DISCOVERY
Challenges of the CNS Drug Discovery and Development
-Alex Nivorozhkin
Chief Scientific Officer
Cybin
DESIGN & SYNTHESIS
Emerging Trends in Medicinal Chemistry: Small Molecule Analog Synthesis and Structure-Activity Relationship (SAR) Strategies
-Matthew Lucas
VP of Medical Chemistry
Third Harmonic Bio
Roundtable Tracks
2Overcoming Challenges And Achieving Resilience: The Future of Biotech and Biopharma – AI-Guided In Drug Discovery and Development (Topic TBC)
INNOVATIVE AND EMERGING MODALITIES
Novel Chemical Modalities
-Sonela Cavicke
Vice President of Discovery Business Development
Sai Life Sciences Ltd
CHEMICAL BIOLOGY, TARGETED PROTEIN DEGRADATION & UNDRUGGABLES
Approaches to ‘Undruggable’ Targets – Targeted Protein Degradation, Chemical Biology and beyond
-Andrew L. Roughton, Ph.D
WuXi AppTec Co., Ltd.
HIT IDENTIFICATION / LEAD OPTIMIZATION
RNA Therapeutics Beyond Antivirals
-Carlos Pedraza
AVP Biology
Sai Life Sciences
INTEGRATED DRUG DISCOVERY
Strategies for implementation of modern and innovative integrated drug discovery towards emerging drug modalities
-Sam Baskaran
Director, Medicinal Chemistry
WuXi AppTec
DESIGN & SYNTHESIS
Efficient Hit-to-Lead Design, Synthesis, and Screening Strategies for Drug Discovery
Roundtable Tracks
3Strategic Partnerships in the Age of AI/ML: Maximizing Value through Collaboration
-Robert Goodnow
Head Drug Discovery Sciences
Takeda
INNOVATIVE AND EMERGING MODALITIES
Advancing Drug Discovery: Exploring Innovative Modalities with Small Molecules in Pre-clinical Development
-Ed Olhava
Senior Vice President, Preclinical Development
IFM Therapeutics
CHEMICAL BIOLOGY, TARGETED PROTEIN DEGRADATION & UNDRUGGABLES
Tackling Drug Resistance and Undruggable Targets
-Sejal Patel
Vice President Chemistry
Scorpion Therapeutics
HIT IDENTIFICATION / LEAD OPTIMIZATION
Investigating Best Strategies To Accelerate The Progress of Compounds From Hit Identification Into Lead Optimization
-Ivan Efremov
VP, Head of Medicinal Chemistry
Nereid Therapeutics
INTEGRATED DRUG DISCOVERY
Translation Gap: Challenges in Translating Promising Drug Candidates to Clinical Success
-Blaise Lippa
Chief Scientific Officer
Morphic Therapeutics
DESIGN & SYNTHESIS
SAR Considerations for CNS-Active Small Molecules: Strategies and Challenges
-Allen Hopper
VP Drug Discovery
Lucy Therapeutics
Roundtable Tracks
4The Practical Application Of AI To Drug Discovery: What’s Required For Success
-Dr. Tamsin Mansley
President and Global Head of Application Science
Optibrium Inc.
INNOVATIVE AND EMERGING MODALITIES
The Most Recent Advancements in Small Molecule Drug Design, Development, and Synthesis In Drug Bioavailability
CHEMICAL BIOLOGY AND UNDRUGGABLES
Moving Towards the Clinic: Preclinical PK and Safety Studies of PROTACs in Targeted Protein Degradation
HIT IDENTIFICATION / LEAD OPTIMIZATION
Rethinking Drug Design & Discovery in the Era of Generative AI
-Norman Azoulay
Director – Scientific Products
Excelra
INTEGRATED DRUG DISCOVERY
Collaborative Platforms for Drug Discovery: Enabling Data Sharing and Collaboration
DESIGN & SYNTHESIS
Using An Integrated CRO/CDMO Service To Accelerate Drug Discovery And Development
-Kaicheng Zhu
Head of Operations, Boston
Bellen
Roundtable Tracks
5Harnessing AI/ML in RNA Modeling and Cheminformatics: From Sequence Analysis to Drug Design
-Aaron Frank
Director and Head of Computational Chemistry
Arrakis Therapeutics
INNOVATIVE AND EMERGING MODALITIES
The Most Recent Advancements in Small Molecule Drug Design, Development, and Synthesis in Drug Bioavailability
-Kevin Kreutter
Vice President, Drug Discovery
Empress Therapeutics
CHEMICAL BIOLOGY AND UNDRUGGABLES
Utilizing The New Warheads: Strategic Ways Of Developing Targeted Covalent Drugs
-Shankar Venkatraman
Executive Director, Chemistry
IFM Therapeutics
HIT IDENTIFICATION / LEAD OPTIMIZATION
Supercharging Drug Discovery: Accelerating Hit Identification and Lead Optimization for Rapid Development
-Horst Hemmerle
Chief Scientific Officer
Kojin Therapeutics
INTEGRATED DRUG DISCOVERY
RNA-Targeted Drug Discovery: Advances in Hit Identification and Lead Optimization Strategies
-Dominic Reynolds
Senior Vice President, Head of Drug Discovery
Remix Therapeutics
DESIGN & SYNTHESIS
Lipid Nanoparticles (LNPs) in Medicinal Chemistry: Synthesis, Formulation, and Delivery Optimization
-Ching Kim Tye
mRNA Director, LNP Platform Development
Sanofi
Reasons To Attend the Strategy Meeting
Discussions on the advancements in targeted protein degradation andrnpushing past its boundaries.
Leveraging Artificial Intelligence and Machine Learning in accelerating therndevelopment of new drugs
Discuss approaches to further understand the interactions of undruggablerntargets and different Protein Degraders such as PROTACs, Molecular Glues,rnetc
Focusing on advancing interrogative techniques to improve the Drug Delivery System/Discovery: Modified mRNA, Nanoparticle-Mediated siRNA, Antibody-Drug Conjugates, and more
Our 2023 Lead Sponsor
Our 2023 Thought Sponsor
Our 2023 Co-Hosts
Our 2023 Key Opinion Leader
Our 2023 Exhibitor
Our Media Partners
Our Supporting Partner
Press play to hear what your colleagues had to say…
Hotel & Venue
Le Méridien Boston Cambridge
Le Méridien Cambridge-MIT’s elegant guest rooms and suites offer a place of luxurious sanctuary and unmatched comfort. Explore unique programs inspired by the brand’s European heritage. Born in a glamorous era of travel, Le Méridien believes everyone should explore the world in style.
Hotel Details Maps & Direction Parking
Want to find out more?
Find out more details about our Strategy Meetings and other news and events.
Here To Help
Want to know more? Interested in sponsoring the event? Need help registering your team? Just get in touch and a member of the team will be happy to help.
Registering online is quick and easy. Simply click the appropriate button below to start the registration process:
- About you
- About your company
- Payment
About Your Company
This is required field*
This is required field*
This is required field*
This is required field*
This is required field*
This is required field*
This is required field*
This is required field*
1*** Please read our Terms of Service and Privacy Policy
No need to enter card details.
Card details
Thanks for your order!
Your registration was successful. You should receive an email shortly confirming your order.
We’re processing your registration and you will recieve further information within 48hours. If you would like a full receipt please email accounts@proventainternational.co.uk
Please quote this when emailing or calling us for any booking related enquires.
Something went wrong. Try again!
Something wasn’t quite right. You can try to make a card payment again otherwise please get in touch at registration@proventainternational.com
Please quote this when emailing or calling us for any booking related enquires.
Order summary for
Bioprocesses Oncology Europe
Payment Securely powered by stripe
